



PRIOR AUTHORIZATION CONSIDERATIONS FOR KITE CAR T THERAPIES

Information provided as a courtesy for background purposes. It is in no way a guarantee of reimbursement or coverage for any product or service. Requirements are subject to change and individual health plans may require other information. Healthcare providers are responsible for accurate submission of claims and contacting payers for the latest guidance.

CAR T=chimeric antigen receptor T cell.

Prior Authorization (PA) Overview

✓ Understand the health plan's specific processes and requirements

✓ Consider the following:



If a coverage decision can be expedited through a peer-to-peer discussion with the health plan's medical director



Whether medical records should be sent to the health plan's medical director prior to the peer-to-peer discussion

PA Considerations

The below information can be used as a reference for what to consider prior to the submission of a PA

Authorized Treatment Center

- Statement of medical necessity
- Health plan's requirements and PA form
- Confirmation of setting of care
- Code submission/information if specific codes are required for hospital and professional services for each step of treatment as required by the patient's health plan
- Scheduled a discussion between the medical director of the health plan and the patient's oncologist regarding coverage

Authorized Treatment Center or referring oncologist

- Patient authorization and notice of release of information
- All prerequisite information, such as the patient's history, medical record information, etc, submitted in advance of the discussion
- Copy of the patient's health-plan card
- Other supporting documentation:
 - » Patient's history and physical findings
 - » Physician's medical record
 - » List of treatments previously provided without success
 - » List of current medications
 - » Laboratory and ancillary tests and results

Information provided as a courtesy for background purposes. It is in no way a guarantee of reimbursement or coverage for any product or service. Requirements are subject to change and individual health plans may require other information. Healthcare providers are responsible for accurate submission of claims and contacting payers for the latest guidance.

KITE and the Kite Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc.
 © 2022 Kite Pharma, Inc. All rights reserved. | US-PTFP-0083 06/2022